Journal of the American Heart Association · 2026
Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.
СтатьяМногоцентровое исследованиеСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Soo-Jin, Her Ae-Young, Joo Hyung Joon, Chang Kiyuk, Kim Byeong-Keuk, Song Young Bin, Ahn Sung Gyun, Suh Jung-Won, Lee Sang Yeup, Cho Jung Rae, Kim Hyo-Soo, Jeong Young-Hoon, Kim Moo Hyun, Lim Do-Sun, Shin Eun-Seok
Аннотация
BACKGROUND: Dual-antiplatelet therapy is standard after percutaneous coronary intervention, but clopidogrel responsiveness varies with CYP2C19 loss-of-function alleles. Whether the genotype conveys different prognostic significance between sexes is uncertain.
METHODS: We analyzed 4630 East-Asian patients with acute coronary syndrome in the PTRG-DES (Platelet Function- and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) consortium with available CYP2C19 genotyping. Patients were classified as rapid/normal metabolizers versus intermediate/poor metabolizers. The primary end point was cardiac death, myocardial infarction, or definite stent thrombosis within 5 years.
RESULTS: Among 4630 patients with acute coronary syndrome, 1708 (36.9%) were women. The prevalence of intermediate/poor metabolizer phenotypes was similar in women (61.8%) and men (62.5%). After multivariable adjustment for clinical, laboratory, and procedural confounders, intermediate/poor metabolizer carriers had a significantly higher risk of the 5-year primary outcome in men compared with rapid/normal metabolizer carriers (adjusted hazard ratio [HR], 3.27 [95% CI, 1.58-6.74]; P=0.001). In contrast, no significant association was observed in women (adjusted HR, 1.21 [95% CI, 0.58-2.52]; P = 0.615). Intermediate/poor metabolizer status was also associated with a higher risk of 5-year cardiac death in men only (adjusted HR, 7.01 [95% CI, 2.01-24.48]; P=0.002). Significant interactions between sex and CYP2C19 metabolizer status were observed for both the primary outcome (P for interaction=0.034) and cardiac death (P for interaction=0.049).
CONCLUSIONS: CYP2C19 loss-of-function allele status was a significant predictor of long-term adverse cardiovascular outcomes in men but not in women, suggesting a sex-specific prognostic difference in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04734028.
METHODS: We analyzed 4630 East-Asian patients with acute coronary syndrome in the PTRG-DES (Platelet Function- and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) consortium with available CYP2C19 genotyping. Patients were classified as rapid/normal metabolizers versus intermediate/poor metabolizers. The primary end point was cardiac death, myocardial infarction, or definite stent thrombosis within 5 years.
RESULTS: Among 4630 patients with acute coronary syndrome, 1708 (36.9%) were women. The prevalence of intermediate/poor metabolizer phenotypes was similar in women (61.8%) and men (62.5%). After multivariable adjustment for clinical, laboratory, and procedural confounders, intermediate/poor metabolizer carriers had a significantly higher risk of the 5-year primary outcome in men compared with rapid/normal metabolizer carriers (adjusted hazard ratio [HR], 3.27 [95% CI, 1.58-6.74]; P=0.001). In contrast, no significant association was observed in women (adjusted HR, 1.21 [95% CI, 0.58-2.52]; P = 0.615). Intermediate/poor metabolizer status was also associated with a higher risk of 5-year cardiac death in men only (adjusted HR, 7.01 [95% CI, 2.01-24.48]; P=0.002). Significant interactions between sex and CYP2C19 metabolizer status were observed for both the primary outcome (P for interaction=0.034) and cardiac death (P for interaction=0.049).
CONCLUSIONS: CYP2C19 loss-of-function allele status was a significant predictor of long-term adverse cardiovascular outcomes in men but not in women, suggesting a sex-specific prognostic difference in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04734028.
Предметные рубрики MeSH
HumansCytochrome P-450 CYP2C19Drug-Eluting StentsFemaleMaleSex FactorsPercutaneous Coronary InterventionAcute Coronary SyndromeMiddle AgedAgedGenotypePlatelet Aggregation InhibitorsRisk FactorsClopidogrelTreatment OutcomePharmacogenomic VariantsPhenotypeMyocardial InfarctionPrognosisTime FactorsCoronary Thrombosis